NEW YORK, Feb. 07, 2019 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical stage biotechnology company, rang the Nasdaq MarketSite bell in Times Square today in celebration of its initial public offering (IPO) on The Nasdaq Stock Market.
Alector is pioneering immuno-neurology, a novel therapeutic approach to counteract the multiple pathologies that cause degenerative brain disorders by restoring healthy immune function to the brain. Supporting its scientific approach, the Company’s Discovery Platform enables them to advance a broad portfolio of product candidates, validated by human genetics, which they believe will improve the probability of technical success of these product candidates and shorten the development timelines to bring these therapies to patients.
“At Alector, we are pioneering immuno-neurology, a new approach for the treatment of neurodegenerative disorders with high unmet need. We are combining integrated insights from human genetics and immunology to advance a number of programs, with our initial focus on Alzheimer’s disease and frontotemporal dementia,” said Arnon Rosenthal, Ph.D., co-founder and chief executive officer of Alector. “We are excited to be joining The Nasdaq Stock Market as we work to advance our programs and bring treatments to patients.”
“Alector is leveraging a novel approach to broadly address multiple neurodegenerative disorders by engaging the brain’s immune system,” said Nelson Griggs, President of the Nasdaq Stock Exchange. “We are so excited to welcome them to the Nasdaq family of the most innovative companies in the world, and look forward to see how they continue to make strides in the biotechnology sector.”
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 100 marketplaces in 50 countries. Nasdaq is home to over 4,000 total listings with a market value of approximately $12 trillion. To learn more, visit business.nasdaq.com.
MEDIA RELATIONS CONTACT:
|
|
– NDAQG –
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/26cd3008-9209-4355-bea8-d2576d26f63a